The Antifungal Drugs Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
New York, NY -- (SBWIRE) -- 04/04/2017 -- Antifungal Drugs Market: Drivers and Challenges
According to Center of Disease Control and Prevention (CDC) approximately 46,000 new cases of Invasive candidiasis occur every year in U.S. which is a common bloodstream infection in U.S. The incidence rate of fungal infections such as Candida species causing infection vary substantially by geographic location and patient population and it is therefore causing challenge to healthcare professionals. The antifungal drugs market is mainly driven by the incidence and prevalence rate of the antifungal infections. Moreover due to benefits such as cost effective products, growing population of immunocompromised individuals and minimal side-effects physician are prescribing these products. Healthcare professionals are conducting patient education program for creating the awareness among the general population. However antifungal drugs market has some restraints such as presence of alternative therapies may hinder the growth of the antifungal drugs market.
A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/11671
With the fungal disease leading to increase in the incidence of fungal infections Antifungal drugs market is increasing very rapidly. Moreover significant rising awareness among general population and rise in disposable income will boost the Antifungal drugs market during the forecast period.
Antifungal Drugs Market: Regional Overview
Geographically the Antifungal drugs market is segmented into five key regions: North America, Latin America, Europe, Asia Pacific and MEA region.
In the United States, Candidemia is the common form of invasive candidiasis and a common bloodstream infections. North America followed by Europe is dominating the Antifungal drugs market as high incidence of fungal infections and development of novel antifungal biopharmaceuticals. In Asia Pacific region the antifungal drugs market is expected to deliver significant growth due to the rise in per capita income in this region which is expected to further fuel market demand. This growth is also due to the increasing awareness towards personal safety and health care. China is expected to register significant market growth in antifungal drugs owing to the growing access of public with healthcare professional and growing economy. Also the antifungal drugs market is expected to become highly competitive due to entry of potential entrants in the market by the end of forecast period.
To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/11671
Antifungal Drugs Market: Key Players
Some major companies in the Antifungal drugs market are Pfizer, Sanofi-Aventis, Kramer Laboratories, Enzon Pharmaceuticals, Abbott Laboratories, Novartis, Merck & Co., Bayer Healthcare and Glaxosmithkline Gilead